Atossa Therapeutics Interest Expense 2011-2026 | ATOS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Atossa Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
-6 K	-223 K	-70 K	-146 K	-91 K	51 K	25.6 K	29.3 K	154	-	-	15.8 K	360	12 K	18 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
51 K	-223 K	-29.5 K

Quarterly Interest Expense Atossa Therapeutics

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-28 K	-11 K	-28 K	-24 K	-	-136 K	-17 K	-36 K	-	-35 K	-30 K	-33 K	-	194 K	-88 K	-40 K	-	-39 K	-35 K	-7 K	-	17.7 K	29.7 K	-10.4 K	-	12.3 K	23.5 K	-8.98 K	-	104	79	59	-	-	-	-	-	-	-	-	-	69.3 K	48.6 K	1.78 K	-	151	1.44 K	749	-	1	352	7	-	7.76 K	2.45 K	1.61 K	-	758	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
194 K	-136 K	-5.1 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 3.13	-	$ 651 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 32.59	-6.89 %	$ 877 M	USA
Forte Biosciences FBRX	-396 K	$ 21.59	-1.86 %	$ 280 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
BioNTech SE BNTX	14.2 M	$ 92.14	1.33 %	$ 22.3 B	Germany
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.7	3.03 %	$ 452 M	Britain
Heron Therapeutics HRTX	1.34 M	$ 0.86	-1.42 %	$ 143 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	2.15 M	-	-	$ 384 M	Britain
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Compugen Ltd. CGEN	281 K	$ 2.8	7.28 %	$ 262 M	Israel
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Incyte Corporation INCY	25.1 M	$ 97.16	-0.26 %	$ 19 B	USA
Ionis Pharmaceuticals IONS	17.3 M	$ 75.56	-0.29 %	$ 12.1 B	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.4	-1.16 %	$ 5.6 M	Israel
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Coherus BioSciences CHRS	9 M	$ 1.61	2.55 %	$ 189 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA